Ab­b­Vie adds de­pres­sion in­di­ca­tion to Vray­lar's la­bel months af­ter Gon­za­lez touts $4B+ peak sales po­ten­tial

Ab­b­Vie CEO Richard Gon­za­lez wants to bring Vray­lar to new heights. On Fri­day, reg­u­la­tors set the next phase of his plan in mo­tion.

The FDA ap­proved Vray­lar, al­so known as cariprazine, as an add-on ther­a­py for adults with ma­jor de­pres­sive dis­or­der (MDD), one of the most com­mon men­tal dis­or­ders in the US. That marks Vray­lar’s fourth in­di­ca­tion be­hind schiz­o­phre­nia, the acute treat­ment of man­ic or mixed episodes in those with bipo­lar I dis­or­der, and de­pres­sive episodes in bipo­lar I pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER